37 results about "Amino acid sequence homology" patented technology

Provided are methods for calculating codon pair translational kinetics values, creating a synthetic gene for expression in a host organism, and providing codon pair translational kinetic values. The methods typically are directed to refinement of statistical observed versus expected codon pair frequencies using one of several factors such as amino acid sequence homology, secondary or tertiary structural considerations, and empirical measurements. In some synthetic genes codon pairs are predicted not to cause a translational pause in the host organism, thereby providing a polynucleotide sequence encoding the desired polypeptide with desired translational kinetics properties. The methods can be performed using multiple parameter nucleotide sequence optimization methods, such as branch-and-bound methods for nucleotide sequence refinement.

Provided in the present invention are recombinant peptides and a method for using the peptides in stimulating an immune response against human high molecular weight-melanoma associated antigen (HMW-MAA). The peptides were designed from the identification of regions of structural and amino acid sequence homology between HMW-MAA and the mouse anti-idiotypic monoclonal antibody MK2-23. The method comprises the step of administering to an individual a peptide of the invention in an amount effective to elicit an immune response against HMW-MAA.

A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

The invention provides L-threonine aldolase. The L-threonine aldolase has the activity of asymmetric catalytic synthesis of (2S,3R)-methylsulfonylphenylserine from methylsulfonyl benzaldehyde and glycine. The L-threonine aldolase is selected from any one of the following groups: (1) polypeptide with the amino acid sequence shown in SEQ ID NO: 1; (2) polypeptide with the amino acid sequence shown in SEQ ID NO: 1, wherein the homology of the amino acid sequence is greater than or equal to 80%; and (3) derived polypeptide formed by substituting, missing or adding of 1-5 amino acid residues of theamino acid sequence shown in SEQ ID NO: 1 and retaining catalytic activity. The invention further provides application of the L-threonine aldolase to synthesis of the methylsulfonylphenylserine, an L-threonine aldolase gene derived from Actinocorallia herbida is mined and screened, the L-threonine aldolase derived from recombinant escherichia coli is expressed through a gene engineering technology, the (2S,3R)-methylsulfonylphenylserine is subjected to asymmetric catalytic synthesis by taking the methylsulfonyl benzaldehyde and the glycine as raw materials and adopting a whole-cell catalysismethod, and the reaction conditions are mild and environmentally friendly.

The present invention relates to the field of biochemistry, in particular to an enzyme co-expression system and its application in synthesizing sialic acid. The present invention provides an N-acetylneuraminic acid aldolase (NAL) mutant having the amino acid sequence shown in SEQ ID NO: 1; or a substitution, deletion, addition and / or substitution 1 on the basis of the above amino acid sequence A sequence of one or more amino acids; or a sequence with more than 90% homology to the above amino acid sequence. The dual-promoter co-expression system adopted in the present invention simultaneously adopts the molecular biological means of increasing expression, realizes the simultaneous overexpression of two enzymes, and realizes the preparation of enzyme liquid by one-time sterilization process, thereby improving the reaction efficiency of the enzyme-catalyzed reaction. . At the same time, for Clostridium Fusarium ( Clostridium scindens ) NAL was modified to improve the synthesis efficiency of the forward reaction to produce sialic acid. The yield of the enzyme-catalyzed process in the present invention meets the requirements of industrial production.

Juvenile hormone acid methyltransferase gene was cloned using a cDNA derived from the corpora allata of Bombyx mori by differential display methods. A recombinant protein expressed in Escherichia coli, which was transformed with a vector DNA incorporating the gene, was found to have juvenile hormone acid methyltransferase activity. Based on amino acid sequence homology, juvenile hormone acid methyltransferase genes were found from Drosophila melanogaster, Anopheles gambiae, Spodoptera litura, and Helicoverpa armigera. The proteins encoded by the juvenile hormone acid methyltransferase genes derived from Drosophila melanogaster, Spodoptera litura, and Helicoverpa armigera were found to have juvenile hormone acid methyltransferase activities.

The invention relates to a protein encoding sequence of pig nuclear receptor coactivity factor 1 gene, which includes No.1-4323 nucleotide sequence in SEQ ID NO.1, with the human, rat species NCOA-1 / SRC-1 gene CDS sequence consanguinity being 93.73%, it has polypeptide of the amino acid sequence represented by SEQ ID NO.1, or its conservative variation polypeptide, of its active segments, or its active derivative, with the human, rat and mouse amino acid sequence consanguinity being 94.99%. The invention can be applied for providing animal models for the research of human mammary cancer, diabetes, obesity and related diseases.

The invention discloses a fusion antigen of avian adenovirus Hexon and chicken infectious bursal disease virus VP2, a subunit vaccine, a preparation method and application thereof. The invention relates to a fusion antigen of avian adenovirus Hexon and chicken infectious bursal disease virus VP2, wherein the fusion antigen includes avian adenovirus Hexon protein and chicken infectious bursal disease virus VP2 protein. The fusion antigen has the following amino acid sequence: (1) a protein consisting of the amino acid sequence shown in SEQ ID No.1; or (2) a homology of 95% to 100 to the amino acid sequence defined by SEQ ID No.1 % amino acid sequence encoding the same functional protein. The protective antigen of the subunit vaccine prepared by the invention is a fusion antigen, which is produced by genetic engineering fermentation, and has the advantages of low cost, high antigen purity, good immunogenicity and high safety.

The invention belongs to the fields of biotechnology and botany; in particular, it relates to a transcription factor for improving stress resistance of plants ScABI3 , having the nucleotide sequence shown in SEQ ID NO.3, other sequences with a homology of not less than 51%; and the amino acid sequence shown in SEQ ID NO.4, other sequences with a homology of not less than 51%. ScABI3 The gene has the function of obviously improving the plant's resistance to adversity stress.

The invention belongs to the field of immunology and specifically relates to a recombinant protein (rPgmp22) of a gametophyte of plasmodium berghei as well as a preparation method and application of the recombinant protein (rPgmp22) to interruption of malaria transmission. The amino acid sequence of the recombinant protein (rPgmp22) of the gametophyte of the plasmodium berghei is SEQ ID NO: 1; the recombinant protein (rPgmp22) is an amino acid sequence with 95-100% of homology with the amino acid sequence limited by SEQ ID NO: 1, which is used for coding a protein with same function; or the recombinant protein (rPgmp22) is a derived pretein with the same activity, which is formed by increasing, deleting or replacing one or a plurality of amino acids for the amino acid sequence shown by SEQ ID NO: 1. The recombinant protein is a novel recombinant protein with a transmission interruption effect, so that the malaria transmission interruption effect can be further improved.

The invention belongs to the field of immunology and particularly relates to Plasmodium berghei gametophyte recombinant protein (rPbG37), a preparation method thereof and application of the Plasmodium berghei gametophyte recombinant protein (rPbG37) in malaria transmission blocking. The amino acid sequence of the Plasmodium berghei gametophyte recombinant protein (rPbG37) is as shown in SEQ ID No. 1; or the amino acid sequence of the Plasmodium berghei gametophyte recombinant protein (rPbG37) is an amino acid sequence whose homology with an amino acid sequence defined by the sequence as shown in SEQ ID No. 1 is 95-100% and encoding identical functional protein; or the amino acid sequence of the Plasmodium berghei gametophyte recombinant protein (rPbG37) is an amino acid sequence obtained by increasing, deleting or replacing one or more amino acid of the amino acid sequence as shown in SEQ ID No. 1 and provided with identical-activity derivative protein. The recombinant protein is novel recombinant protein with a transmission blocking effect and can further increase a malaria transmission blocking effect.

The invention belongs to the field of biotechnology and botany and particularly relates to a transcription factor ScABI3 with a function of improvement of plant stress resistance. The transcription factor has a nucleotide sequence shown as SEQ ID NO.3 and other sequences in homology not lower than 51% and further has an amino acid sequence shown as SEQ ID NO.4 and other sequences in homology not lower than 51%. The ScABI3 gene has the function of evident improvement of plant stress resistance.

The invention provides a kiwifruit germplasm material with strong resistance to an extreme high-temperature growth condition and a cultivation method. The kiwifruit germplasm material is obtained by over-expressing a heat shock transcription factor HsfA2-1. The kiwifruit germplasm material has extremely high resistance in the aspect of high temperature stress resistance, can continuously resist extreme high temperature stress of 50 DEG C for at least 2 hours, and can continuously and normally grow after being stressed. According to the invention, a heat shock transcription factor AcHsfA2-1 in Donghong kiwi fruit is taken as an example, and the cultivation method of the germplasm material is elaborated. The application of other genes, of which the homology with the nucleotide sequence or amino acid sequence of the AcHsfA2-1 is higher than 90%, in the aspect is within the protection range of the invention. The cultivation method is reasonable in design, convenient to operate and easy to popularize and apply.

The invention provides application of L-threonine transaldolase to synthesis of florfenicol chiral intermediates. The L-threonine transaldolase is selected from any one of the following groups that (1) polypeptide contains an amino acid sequence shown in SEQ ID NO:1; (2) polypeptide contains an amino acid sequence greater than or equal to 90% homology shown in SEQ ID NO:1, and the polypeptide hascatalytic activity; and (3) derived polypeptide is formed by substitution, deletion or addition of 1-5 amino acid residues to the amino acid sequence shown in SEQ ID NO:1 and with the retention of catalytic activity. According to the application, new L-threonine transaldolase genes are screened through gene mining, the L-threonine transaldolase derived from recombinant escherichia coli is expressed by adopting a genetic engineering method, methylsulfonyl benzaldehyde and the L-threonine transaldolase are used as raw materials, (2S,3R)-methylsulfonyl phenylserine is synthesized through a wholecell catalyzed reaction, fluorfenicol key chiral synthesis blocks can be obtained by a one-step reaction under the room temperature and pressure, environmental protection is achieved, and the application is an environment-friendly biosynthetic pathway.

The invention discloses an alcohol dehydrogenase mutant and application thereof. The amino acid sequence of the alcohol dehydrogenase mutant is an amino acid sequence obtained by mutating an amino acid sequence as shown in SEQ ID NO:9; the mutated amino acid sequence has at least one mutation site selected from the following mutation sites: the 40th position, the 87th position, the 194th position and the 331st position; T on the 40th position is mutated into S, A or C; W on the 87th position is mutated into F, Y or H; V on the 194th position is mutated into I, L or E; R on the 331st position is mutated into A, K or M; or the amino acid sequence of the alcohol dehydrogenase mutant has the mutation sites in the mutated amino acid sequence, and the alcohol dehydrogenase mutant contains more than 90% of amino acid sequences which are homologous with the mutated amino acid sequence. The stereoselectivity and enzyme activity of the alcohol dehydrogenase mutant which is provided with the at least one mutation site or retains the mutation site and contains more than 90% of amino acid sequences which are homologous with the mutated amino acid sequence are greatly improved.

The present invention relates to the technical field of rabies application, in particular to a rabies virus recombinant antigen and a preparation method and use thereof, including one of the following (a)-(c): (a), in the direction from the N-terminal to the C-terminal, including Such as amino acid sequence fragments N, G and P; (b), amino acid sequence fragments N, G and / or P in (a) have been substituted, deleted or added at least one or several amino acid recombinant antigens of rabies virus, and can be Inducing an immune response in a mammal against the rabies virus recombinant antigen; or (c), an amino acid sequence having homology to the amino acid sequence of the rabies virus recombinant antigen in (a), and eliciting a mammal against the rabies virus Immune response of recombinant antigens; the above-mentioned rabies virus recombinant antigens have antigenic epitopes with good antigenicity and non-specificity, and have the advantages of stability, safety, low culture cost and high efficiency compared with holovirus antigens.